Monte Rosa (GLUE) shares rise as it teams with Johnson & Johnson to test MRT-2359 + ERLEADA in mCRPC AR mutations in a Phase ...

MRT-2359 is an investigational, orally bioavailable, GSPT1-directed molecular glue degrader that has shown compelling clinical activity in ...

The 2026 European Association of Urology (EAU) annual meeting featured an advancement in metastatic castration resistant ...

Real-world PRECISION data in 500 taxane-naïve, PSMA-positive mCRPC patients showed median PFS 13.5 months (95% CI, 11.7–14.7), aligning with PSMAfore efficacy expectations. Earlier sequencing mattered ...

The 2026 European Association of Urology (EAU) annual meeting featured an advancing prognostics and therapeutics in ...

In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate ...

Metastatic castration-resistant prostate cancer (mCRPC) is a type of advanced prostate cancer that has spread to other parts of the body. It no longer responds to treatments that block testosterone, a ...

The term metastatic castration-resistant prostate cancer (mCRPC) refers to a cancer that has spread (metastasized) beyond your prostate gland and for which hormone therapy is no longer effective in ...

Bayer today announced results from the ongoing global Phase I first-in-human, dose-escalation PAnTHa study (NCT06217822) evaluating the safety, tolerability and preliminary efficacy of ...

Results suggest bone-protecting agents should be used in patients with metastatic castration-resistant prostate cancer and bone metastasis, especially in the era of androgen receptor pathway ...

MRT-2359 is an investigational, orally bioavailable, GSPT1-directed molecular glue degrader that has shown compelling clinical activity in combination with androgen receptor (AR) inhibition in heavily ...